Table 1. Involvement of different molecular mechanisms in memory destabilisation before and after its reactivation in the amygdala.

Timing	Target	Reference	Task	Species	Drug	Infusion Time	Reconsolidation Inhibitor		Outcome
Pre-reexposure	NMDA	[6]	AFC	Rat	AP5 / Ifenprodil	10 min		Anisomycin		Blocks destabilisation
		[7]	AFC	Rat	Ifenprodil	Immediately		Anisomycin		Blocks destabilisation
		[22]	CFC	Mouse	Ifenprodil	5 min		Anisomycin		Blocks destabilisation
		[14]	CPP	Mouse	MK-801 / Ifenprodil	30 min		Anisomycin		Blocks destabilisation
		[14]	CPP	Mouse	NVP-AAM077	30 min		Anisomycin		No effect
	AMPA	[23]	CTA	Rat	NBQX	20 min		Anisomycin		Impairs retrieval
		[7]	AFC	Rat	LY293558	Immediately		Anisomycin		No effect
	GluA2 endocytosis	[10]	AFC	Rat	Tat-GluA23Y	60 min		Anisomycin / NASPM		Blocks destabilisation
		[12]	AFC	Rat	Tat-GluA23Y	15 min		Anisomycin + tBC		Blocks destabilisation
	Calcineurin	[13]	IA	Mouse	FK506	5 min		Anisomycin		Blocks destabilisation and memory enhancement
		[14]	CPP	Mouse	CyA / FK506	30 min		Anisomycin		Blocks destabilisation
	Dopamine receptors	[9]	AC	Rat	SCH23390 / Raclopride	Immediately		Anisomycin		Blocks destabilisation
		[9]	AC	Rat	α-flupenthixol	Immediately		Anisomycin		No effect
	PP1	[14]	CPP	Mouse	Calyculin A / Okadaic acid	30 min		Anisomycin		Blocks destabilisation
	Autophagy	[12]	AFC	Rat	Spautin-1	15 min		Anisomycin		Partially blocks destabilisation
		[12]	AFC	Rat	tBC	15 min		Anisomycin		Enhances destabilisation
Post-reexposure	NMDA	[6]	AFC	Rat	AP5 / Ifenprodil	Immediately		Anisomycin		No effect
	UPS	[11]	CFC / AFC	Rat	β-lactacystin	Immediately		Anisomycin		Blocks destabilisation
		[13]	IA	Mouse	β-lactacystin	Immediately		Anisomycin		Blocks destabilization and memory ennhancement
	CaMKII	[15]	CFC	Rat	Myr-AIP	Immediately		Anisomycin		Blocks destabilisation

Table shows the time of infusion, target molecule, reference, behavioural task, species, drugs used to block reconsolidation and destabilisation and behavioural outcome. All reconsolidation and labilization blockers were injected in the amygdala. α-flupenthixol, non-subtype selective dopamine receptor antagonist; β-lactacystin, clasto-Lactacystin-b-lactone; AC, appetitive conditioning; AFC, auditory fear conditioning; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; AP5, 2-amino-5-phosphopentanoic acid, NMDA antagonist; Calyculin A, PP1 inhibitor; CaMKII, calcium–calmodulin dependent protein kinase II; CFC, contextual fear conditioning; CPP, conditioned place preference; CTA, conditioned taste aversion; CyA, Cyclosporin A, calcineurin inhibitor; FK-506, calcineurin inhibitor; GluA2, A2 subunit of the AMPA receptor; IA, inhibitory avoidance; Ifenprodil, GluN2B-containing NMDA receptor antagonist; LY293558, AMPA receptor antagonist; MK-801, dizolcipine, NMDA antagonist; Myr-AIP, myristoylated autocamtide-2 related inhibitory peptide, CaMKII inhibitor; NASPM, 1-naphthyl acetyl spermine, Ca⁺⁺-permeable AMPA receptor antagonist; NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline AMPA receptor antagonist; NMDA, N-methyl D-aspartate; NVP-AAM077, GluN2A-containing NMDA receptor antagonist; Okadaic acid, PP1 inhibitor; PP1, protein phosphatase 1; Raclopride, D2 receptor antagonist; SCH23390, D1 receptor antagonist; Spautin-1, inhibitor of ubiquitin-specific peptidases 10 and 13; Tat-GluA2_3Y, interference peptide disrupting GluA2 endocytosis; tBC, retro-inverso Tat-beclin 1 peptide D-amino acid sequence, autophagy inducer; UPS, ubiquitin-proteasome system.